Clinical trial · Observational
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma
NCT01580241CI-TRIAL-00106988active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- Surgery group
- description
- Patients with pancreatic cancer who undergo surgical treatment only
- label
- Chemotherapy group
- description
- Patients with pancreatic cancer who undergo chemotherapy treatment only
- label
- Neoadjuvant group
- description
- Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
- label
- Adjuvant group
- description
- Patients with pancreatic cancer who undergo surgery followed by chemotherapy
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * pancreatic cancer Exclusion Criteria: * age \< 18, history of other types of cancer
References
Publications (0)
Data not yet available
No reference posted for this study.